BLAINJECTIONINJECTABLE
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TYRUKO (natalizumab-sztn) by Novartis is integrin receptor antagonists [moa]. Approved for integrin receptor antagonist [epc]. First approved in 2023.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYRUKO is a monoclonal antibody integrin receptor antagonist approved by the FDA in August 2023 as a Novartis biosimilar referencing natalizumab. It blocks integrin-mediated cell adhesion to reduce immune cell migration into target tissues. The drug is indicated for conditions treated with integrin receptor antagonism, positioning it in the immunology therapeutic space.
Growth
Early-stage growth phase with active commercial build-out; expect expanding team size and new marketing infrastructure development.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Novartis is hiring 1 role related to this product
Worked on TYRUKO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.